



November 8, 2021

Graftys, SA (Belgium) is pleased to announce that it has acquired Biologics4Life. Graftys develops, manufactures and sells synthetic bone graft materials. Biologics4Life is an early-stage company headquartered in France with a strong pipeline of innovative orthobiologic materials which include combinations with active principles to address osteoporosis and metastatic bone disease. The combined organization will deepen development and commercial capabilities to fully leverage its pipeline of patented technologies. As part of this acquisition, Graftys raised an additional \$3M (2.6M Euros) in equity to fund growth. The senior team of Biologics4Life has assumed operational responsibility for Graftys which will remain headquartered in Jumet, Belgium, and operations facilities will be consolidated in Aix-en-Provence, France.

Contacts:

Europe: Sebastien Genesta sebastien.genesta@biologics4life.fr +33 6 78 93 96 05

USA: Ron Lowell ron.lowell@biologics4life.fr +1 847 651 3723